Suntrust Banks Inc. Sells 109 Shares of Pacira Pharmaceuticals, Inc. (PCRX)

Suntrust Banks Inc. decreased its position in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 0.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,328 shares of the company’s stock after selling 109 shares during the quarter. Suntrust Banks Inc.’s holdings in Pacira Pharmaceuticals were worth $682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in PCRX. US Bancorp DE lifted its position in Pacira Pharmaceuticals by 50.5% in the 1st quarter. US Bancorp DE now owns 8,989 shares of the company’s stock worth $410,000 after buying an additional 3,015 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Pacira Pharmaceuticals by 4.2% in the 1st quarter. Bank of New York Mellon Corp now owns 206,435 shares of the company’s stock worth $9,415,000 after buying an additional 8,366 shares during the last quarter. Swiss National Bank lifted its position in Pacira Pharmaceuticals by 2.5% in the 1st quarter. Swiss National Bank now owns 61,300 shares of the company’s stock worth $2,795,000 after buying an additional 1,500 shares during the last quarter. UBS Asset Management Americas Inc. lifted its position in Pacira Pharmaceuticals by 2.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 175,292 shares of the company’s stock worth $7,993,000 after buying an additional 4,592 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Pacira Pharmaceuticals by 788.0% in the 1st quarter. Ameriprise Financial Inc. now owns 282,531 shares of the company’s stock worth $12,884,000 after buying an additional 250,714 shares during the last quarter.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) opened at 36.55 on Friday. The stock’s 50 day moving average price is $37.01 and its 200 day moving average price is $43.33. The stock’s market capitalization is $1.47 billion. Pacira Pharmaceuticals, Inc. has a 1-year low of $29.95 and a 1-year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.06). Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The business had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. During the same period in the prior year, the business posted $0.21 earnings per share. Pacira Pharmaceuticals’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts predict that Pacira Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current fiscal year.

WARNING: This story was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://transcriptdaily.com/2017/10/08/suntrust-banks-inc-sells-109-shares-of-pacira-pharmaceuticals-inc-pcrx.html.

Several analysts have weighed in on the company. Cowen and Company reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday, August 2nd. Goldman Sachs Group, Inc. (The) assumed coverage on Pacira Pharmaceuticals in a research report on Thursday, September 28th. They issued a “neutral” rating and a $41.00 price objective for the company. Zacks Investment Research upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a research report on Tuesday, October 3rd. Mizuho reiterated a “buy” rating and issued a $53.00 price objective (down previously from $54.00) on shares of Pacira Pharmaceuticals in a research report on Tuesday, August 22nd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $44.00 price objective (down previously from $48.00) on shares of Pacira Pharmaceuticals in a research report on Sunday, October 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $52.07.

In other Pacira Pharmaceuticals news, Director Paul J. Hastings sold 1,044 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the transaction, the director now directly owns 3,518 shares in the company, valued at approximately $127,175.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David M. Stack sold 28,885 shares of the firm’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the transaction, the chief executive officer now owns 159,164 shares in the company, valued at $5,788,794.68. The disclosure for this sale can be found here. Insiders have sold a total of 33,390 shares of company stock valued at $1,215,480 over the last three months. 6.60% of the stock is owned by corporate insiders.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply